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2561ejection fraction (LVEF) 35% (1). An unanticipated
ﬁnding of the trial was that patients with NYHA functional
class II heart failure had a 46% reduction in mortality with
ICD therapy, but patients with NYHA functional class III
heart failure did not appear to beneﬁt from ICD therapy
and trended toward harm. In addition, NYHA functional class
II patients obtained no beneﬁt from amiodarone, whereas class
III patients had a statistically signiﬁcant increase in mortality
compared with patients in the placebo group.
NYHA functional classiﬁcation is a widely used and well
accepted measure of functional capacity that has only fair
interobserver reproducibility (2). Nevertheless, it has the
advantage of wide familiarity, easy application, demonstrated
prognostic importance, and no cost. The 6-min walk
(6MW) test shares many of those qualities but adds the
additional advantage of being a more structured, objective
measure of functional capacity (3). Prior investigations have
shown that distance walked during the 6MW test correlates
moderately with NYHA functional class, peak oxygen
consumption, and assessments of quality of life (4–6).
Additionally, 6MW distance has been found to predict
mortality and hospital stay in heart failure patients (7–9).
We postulated that if the differences observed in therapeutic
beneﬁt in SCD-HeFT from amiodarone or ICD therapy
according to NYHA functional class were robust, they
would also be evident using the 6-min walk test.Methods
Design and primary clinical results of SCD-HeFT. The
design of SCD-HeFT has been described previously
(1,10). In brief, 2,521 patients with stable NYHA
functional class II or III heart failure due to ischemic
and nonischemic cardiomyopathy and an LVEF 35%
were randomized to receive placebo, amiodarone, or a
single-lead ICD programmed to shock-only mode with
pacing only for extreme bradycardia. Study protocol
approval was obtained from each site’s institutional re-
view board or ethics committee. Randomization was
stratiﬁed by the presence of coronary disease and NYHA
functional class II or III. NYHA functional class was
assigned by the investigator at enrollment. NYHA
functional class I and IV patients were excluded. In-
vestigators were encouraged to treat study patients with
optimal medical therapy, including an angiotensin-
converting enzyme inhibitor and a beta-blocker as well as
spironolactone, aspirin, and a statin if appropriate. The
primary endpoint of the trial was death from any cause.
Informed consent was obtained from all patients. Patients
were enrolled at 148 sites in the United States, Canada,
and New Zealand from September 16, 1997, to July 18,
2001. All patients were followed until October 31, 2003.
Vital status was known at the end of the trial for 100% of
patients enrolled. Treatment assignment was balanced, with
847 patients assigned to placebo, 845 to amiodarone, and 829
to ICD therapy. No signiﬁcant differences in overall baselinedemographic or clinical charac-
teristics were found among the 3
treatment groups (1).
SCD-HeFT demonstrated that
in patients with NYHA func-
tional class II or III heart failure
and an LVEF 35%, conserva-
tively programmed, single-lead
ICD therapy improved survival
(hazard ratio [HR]: 0.77; 97.5%
conﬁdence interval [CI]: 0.62 to
0.96; p¼ 0.007) (1). The trial also
found no survival beneﬁt from
amiodarone (HR: 1.06; 97.5% CI: 0.86 to 1.30; p ¼ 0.53)
compared with placebo in this cohort. Further, in pre-
speciﬁed subgroup analyses, patients with NYHA functional
class III symptoms at baseline did not beneﬁt from ICD
therapy (HR: 1.16; 97.5%CI: 0.84 to 1.61; p¼ 0.30) andwere
harmed by amiodarone (HR: 1.44; 97.5% CI: 1.05 to 1.97;
p ¼ 0.010).
6MW test. A 6MW test was performed after consent was
obtained prior to randomization. Investigators were given
detailed guidelines for performance of the 6MW test (10),
which was modiﬁed from that described by Guyatt et al. (3).
A 60-foot (18.3 m) course in an enclosed corridor was
marked, and a chair was placed at each end. Patients were
asked to walk at their own pace from chair-to-chair, but
were instructed to cover as much distance as possible during
the allotted 6 min. Patients were allowed to stop and rest
during the test but were instructed to resume walking as soon
as they were able. Standardized verbal encouragement was
provided every 30 s. Coaching or enthusiastic urging were
prohibited. After 6 min, patients were instructed to stop
walking, and the distance covered was recorded. Symptoms of
dyspnea, angina, and/or lightheadedness experienced by the
patient during the walk test were also recorded. The results
were measured in feet and converted to meters in the analysis
to permit easier comparison with prior data.
Data analysis. Medians with interquartile ranges were
used to describe continuous variables. Frequencies and
percents were used to describe categorical variables. To
facilitate descriptive analyses as well as illustration of
multivariable modeling results, 6MW distances were
divided into tertiles, with dividing points at 288 and 386 m.
Baseline characteristics were compared among tertiles using
the Jonckheere-Terpstra test (11) for continuous variables
and the Mantel-Haenszel chi-square test for categorical var-
iables. Incidence of symptom types was also compared among
tertiles using the Mantel-Haenszel chi-square test (11).
Mortality curves were generated using Kaplan-Meier
methods (12). Treating 6MW distance as a continuous var-
iable, Cox proportional hazardsmodels were used to assess the
relationship of 6MW distance to mortality (13). Restricted
cubic splines were used to determine whether the relationship
as characterized with the Cox model was strictly linear (14).
Interactions between 6MW distance and randomized
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2562treatment were tested within themodel to determine whether
the effect of ICD or amiodarone (vs. placebo) varied with
6MW distance. Because these interactions were signiﬁcant,
the relationship of 6MW distance to mortality risk was
estimated within treatment groups separately. Similarly, ICD
and amiodarone HRs (vs. placebo) were estimated using
subgroup models within 6MW tertiles. Comparisons of
amiodarone and ICD with placebo were performed accord-
ing to the intention-to-treat principle. All Cox models
included baseline covariates previously identiﬁed as pre-
dictors of mortality in SCD-HeFT: age, sex, heart failure
etiology (ischemic vs. nonischemic), NYHA functional class,
LVEF, time since heart failure diagnosis, diabetes, mitral
regurgitation, substance abuse, renal insufﬁciency, systolic
blood pressure, PR interval, corrected QT interval, intra-
ventricular conduction delay, and use of an angiotensin-
converting enzyme inhibitor or digoxin. Risk relationships
are expressed as HRs with associated 95% CIs. To compare
the predictive value of NYHA functional class and 6MW
distance, we calculated the incremental model likelihood
ratio chi-square statistics and c-statistics (model with and
without variable of interest but containing all other adjust-
ment variables listed above). These provide a measure of the
“prognostic information content” of each variable after
adjustment for other relevant baseline prognostic factors.Table 1 Baseline Characteristics by 6MW Distan
6
<288
(n ¼ 787)
Randomized treatment
ICD 34% (270)
Amiodarone 33% (261)
Placebo 33% (256)
Age, yrs 64 (55, 71)
Female 32% (254)
Nonwhite race 31% (246)
Weight, lbs 184 (159, 214)
NYHA functional class III 50% (395)
Ischemic HF etiology 57% (446)
Ejection fraction, % 25 (20, 30)
Systolic blood pressure, mm Hg 118 (106, 130)
Serum sodium, mEq/l 139 (137, 141)
Serum creatinine, mg/dl 1.2 (1.0, 1.4)
Diabetes 37% (295)
Hypertension 63% (496)
Current smoker 18% (142)
Pulmonary disease 25% (193)
Atrial ﬁbrillation/ﬂutter 18% (139)
Prior MI 73% (376)
Prior stroke 10% (75)
ACE-I or ARB 95% (744)
Beta-blocker 64% (501)
Values are % (n) or median (25th, 75th percentiles). Race was self-reported
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II r
deﬁbrillator; MI ¼ myocardial infarction; NYHA ¼ New York Heart AssociatioA clinical events committee that was blinded to the pa-
tients’ treatment assignment classiﬁed the cause of death (15).Results
Study population baseline characteristics. A total of
2,397 (95.1%) SCD-HeFT patients performed a baseline
6MW test; 117 patients were unable to perform the test,
and data were missing on 7 patients. There were signiﬁcant
differences in baseline characteristics among tertiles of
6MW distance (Table 1). Shorter 6MW distance was
associated with a higher prevalence of older age, female sex,
nonwhite race, lower weight, NYHA functional class III,
ischemic heart failure etiology, history of diabetes, history
of hypertension, and history of pulmonary disease. There
were no signiﬁcant associations with standard predictors
of heart failure severity including LVEF, systolic blood
pressure, or serum sodium. Biomarkers, such as brain type
natriuretic peptides, were not assessed during the study.
The median 6MW distance for the entire study group was
342 m (25th, 75th percentiles: 255, 412 m). The distribu-
tion of 6MW distance within treatment groups was nearly
identical (Table 2). Patients who walked shorter distances
were more likely to be symptomatic during the test, with
dyspnea as the predominant symptom reported (Table 3).ce Tertile
MW Distance, m
p Value
288–386
(n ¼ 809)
>386
(n ¼ 801)
0.32
32% (262) 32% (256)
34% (273) 34% (275)
34% (274) 34% (270)
59 (51, 68) 57 (49, 65) <0.0001
25% (202) 13% (104) <0.0001
23% (184) 16% (131) <0.0001
189 (161, 221) 195 (169, 222) <0.0001
25% (201) 12% (96) <0.0001
51% (416) 46% (367) <0.0001
25 (20, 30) 24 (20, 30) 0.90
120 (107, 132) 117 (104, 130) 0.14
139 (137, 141) 139 (137, 141) 0.67
1.1 (0.9, 1.3) 1.1 (0.9, 1.3) <0.0001
30% (244) 22% (173) <0.0001
56% (449) 46% (372) <0.0001
17% (135) 14% (111) 0.024
19% (151) 13% (103) <0.0001
14% (111) 13% (106) 0.013
72% (364) 69% (311) 0.21
6% (49) 3% (22) <0.0001
97% (788) 98% (784) 0.0002
71% (571) 73% (584) <0.0001
on the clinical case report form.
eceptor blocker; HF ¼ heart failure; ICD ¼ implantable cardioverter-
n; 6MW ¼ 6-min walk.
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25636MW distance and all-cause mortality. PRELIMINARY
MODEL CHECKING. There were signiﬁcant interactions be-
tween 6MW distance and treatment (ICD or placebo
[p ¼ 0.0006], amiodarone or placebo [p ¼ 0.0004]), indi-
cating that the association of 6MW distance with mortality
risk varied by treatment group and the effect of treatment
varied according to 6MW distance. Subsequent modeling
was done either in treatment subgroups or 6MW distance
tertile subgroups, according to the question being evaluated.
Within each treatment group, the relationship of 6MW
distance to mortality risk as characterized by the log hazard
ratio in the Cox model was linear (all p > 0.7 for nonlinearity
tests), indicating that there was no 6MW distance below
which mortality increased at a substantially accelerated rate.
6MW DISTANCE AND MORTALITY (ASSESSED IN TREATMENT
SUBGROUPS). In patients assigned to placebo, there were 60
deaths (3-year Kaplan-Meier rate: 17.8%) in the highest
6MW distance tertile, 78 deaths (21.6%) in the middle
tertile, and 83 deaths (24.7%) in the lowest tertile (Fig. 1).
In patients assigned to amiodarone, there were 45 deaths
(14.2%) in the highest 6MW distance tertile, 63 deaths
(16.6%) in the middle tertile, and 115 deaths (38.7%) in the
lowest tertile. In patients assigned to ICD therapy, there
were 28 deaths (7.0%) in the highest 6MW distance tertile,
44 deaths (12.4%) in the middle tertile, and 92 deaths
(28.0%) in the lowest tertile.
For placebo patients, the unadjusted HR for each 50-m
increase in 6MW distance was 0.93 (95% CI: 0.88 to
0.98; p ¼ 0.0069). The corresponding adjusted HR was
1.00 (95% CI: 0.93 to 1.06; p ¼ 0.89). Among patients
randomized to amiodarone, the unadjusted HR was 0.80
(95% CI: 0.76 to 0.85; p < 0.0001) and the adjusted HR
was 0.90 (95% CI: 0.84 to 0.96; p ¼ 0.0019) for each 50-m
increase in 6MW distance. For ICD patients, the unad-
justed HR was 0.77 (95% CI: 0.73 to 0.83; p < 0.0001)
and the adjusted HR was 0.88 (95% CI: 0.81 to 0.96;
p ¼ 0.0025) for each 50-m increase in 6MW distance.
6MW DISTANCE AND TREATMENT BENEFIT (ASSESSED IN 6MW
DISTANCE TERTILES). ICD therapy signiﬁcantly reduced
mortality in the top and middle tertiles of 6MW dis-
tance versus placebo (HR: 0.42 [95% CI: 0.26 to 0.66],
p ¼ 0.0002 in the highest tertile and HR: 0.57 [95% CI:
0.39 to 0.83], p ¼ 0.0035 in the middle tertile) but was
neutral in patients with the lowest 6MW distances (HR:
1.02 [95% CI: 0.75 to 1.39], p ¼ 0.90 in the lowest tertile)
(Fig. 2, Table 4). For amiodarone relative to placebo, in the
lowest 6MW distance tertile, amiodarone increased mor-
tality (HR: 1.56 [95% CI: 1.17 to 2.09], p ¼ 0.0028). In the
middle tertile, amiodarone had a relatively neutral effect on
mortality (HR: 0.86 [95% CI: 0.61 to 1.21], p ¼ 0.38). In
the highest tertile, there was a marginal trend toward sur-
vival beneﬁt with amiodarone (HR: 0.68 [95% CI: 0.46 to
1.02], p ¼ 0.061).
6MW distance and cause-speciﬁc mortality. 6MWDISTANCE
AND HEART FAILURE MORTALITY. When the relationship
Table 3 Symptoms During Baseline 6-Min Walk by Distance Tertile
<288 m
(n ¼ 787)
288–386 m
(n ¼ 809)
>386 m
(n ¼ 801) p Value
Asymptomatic 25% (196) 39% (312) 50% (398) <0.0001
Symptomatic 75% (591) 61% (497) 50% (403)
Dyspnea 62% (490) 51% (413) 43% (344) <0.0001
Lightheadedness 12% (97) 8% (67) 4% (33) <0.0001
Angina 6% (46) 6% (46) 3% (28) 0.031
Near syncope 0.4% (3) 0 0 d
Syncope 0 0 0 d
Other 38% (298) 28% (227) 18% (141) <0.0001
Fishbein et al. JACC Vol. 63, No. 23, 2014
6-Min Walk Predicts Treatment Effect June 17, 2014:2560–8
2564between 6MW distance and heart failure deaths was
examined (censoring all other causes of death), an inverse
prognostic gradient of effect was seen for all 3 treatment
arms in the unadjusted data (Fig. 3), with lower 6MW
distance results associated with higher mortality. Un-
adjusted HR for a 50-m increase in 6MW distance: 0.79
for ICD, 0.81 for amiodarone, and 0.87 for placebo (all
p < 0.006). After adjustment, the prognostic gradient for
6MW distance was reduced in magnitude and was no longer
statistically signiﬁcant: the HR for 50-m increase in 6MW
distance was 0.91 for ICD (p ¼ 0.14), 0.94 for amiodarone
(p ¼ 0.36), and 0.94 for placebo (p ¼ 0.37).
Comparing treatments within 6MW distance tertiles after
adjustment and censoring all non–heart failure deaths, the
HR for ICD relative to placebo was 0.73 (95% CI: 0.32 to
1.64) in the top 6MW distance tertile, 0.66 (95% CI: 0.34
to 1.30) in the middle 6MW distance tertile, and 1.22 (95%
CI: 0.73 to 2.03) in the bottom 6MW distance tertile. For
amiodarone, the corresponding HRs were 0.94 (95% CI:
0.41 to 2.19), 1.10 (95% CI: 0.60 to 2.01), and 1.20 (95%
CI: 0.70 to 2.05).
6MW DISTANCE AND ARRHYTHMIC MORTALITY. The unad-
justed relationship between 6MW distance and risk of
arrhythmic deaths (censoring all other causes of death)
varied by treatment group (Fig. 4): the HR for a 50-m in-
crease in 6MW distance was 0.73 for ICD (p < 0.0001),
0.95 for amiodarone (p ¼ 0.30), and 1.05 for placebo (p ¼
0.30). After adjustment, the HR for 50-m increase in 6MW
distance was 0.85 in the ICD arm (p ¼ 0.13), 1.04 in the
amiodarone arm (p ¼ 0.56), and 1.13 in the placebo arm
(p ¼ 0.022).
Comparing treatments within 6MW distance tertiles after
adjustment and censoring all nonarrhythmic deaths, the HR
for ICD relative to placebo was 0.10 (95% CI: 0.03 to 0.33)
(p ¼ 0.0002) in the top 6MW distance tertile, 0.36 (95%
CI: 0.17 to 0.75) (p ¼ 0.007) in the middle 6MW distance
tertile, and 0.72 (95% CI: 0.38 to 1.35) (p ¼ 0.31) in the
bottom 6MW distance tertile. The corresponding HRs for
amiodarone versus placebo were 0.62 (95% CI: 0.35 to 1.12)
(p ¼ 0.11), 0.78 (95% CI: 0.44 to 1.38) (p ¼ 0.39), and 1.06
(95% CI: 0.59 to 1.89) (p ¼ 0.86).Prognostic value of 6MW distance versus NYHA
functional class. Adjusting for baseline clinical and de-
mographic variables but excluding NYHA functional class
and 6MW distance, the model LR chi-square value was
360.8 and c-statistic was 0.702 (Online Table 1). After
adding NYHA functional class, the value increased to 413.4
(incremental chi-square 52.6) and c-statistic increased to
0.716. After adding 6MW distance (and with NYHA
functional class excluded), the value increased to 423.7 (in-
cremental chi-square 62.9) and the c-statistic increased to
0.722.
One of the unexpected ﬁndings of the present investiga-
tion was that 6MW distance was not an independent pre-
dictor of all-cause mortality in the placebo patients (adjusted
HR: 1.0 for 50 m increase in 6MW distance, p ¼ 0.89) but
was an independent prognostic factor in the ICD (adjusted
HR: 0.88, p ¼ 0.0025) and the amiodarone (adjusted HR:
0.90, p ¼ 0.0019) patients. To understand these results, we
did additional exploratory analyses using cause-speciﬁc
mortality analyses (heart failure, and arrhythmic, with all
other deaths censored) within each treatment group. We
found that the 6MW distance had a clear inverse gradient
with heart failure mortality (lowest 6MW distance associ-
ated with highest mortality rate) that was almost identical in
the 3 treatment groups (Fig. 3) (unadjusted HRs: 0.87 for
ICD, 0.88 for amiodarone, and 0.92 for placebo; all p <
0.001). After adjustment, the prognostic gradient with
heart failure mortality was lost for all 3 treatment groups
(HRs: 0.94 for ICD, 0.97 for amiodarone, and 0.96 for
placebo; all p > 0.10). The patterns were more complex
when we examined 6MW distance against arrhythmic death,
censoring other modes of death. In the unadjusted data
(Fig. 4), there was again an inverse gradient of mortality with
6MW distance for ICD and amiodarone, but the relation-
ship in the placebo arm was ﬂat in the lowest and middle
tertiles with a modest increase in the mortality risk in the
highest tertile. Whether this latter effect is a chance variation
in the data or a reproducible feature of the prognostic in-
formation conveyed by the 6MW test cannot be determined
from our data. One additional aspect of note is that,
although the unadjusted patterns of arrhythmic mortality
versus 6MW distance for ICD and amiodarone-treatment
Figure 2
Treatment Effects on Mortality in
6-Min Walk Distance Subgroups
Kaplan-Meier estimates of death from any cause, by treatment group stratiﬁed by
6-min walk distance tertile. CI ¼ conﬁdence interval; HR ¼ hazard ratio; ICD ¼
implantable cardioverter-deﬁbrillator.
Figure 1
6-Min Walk Distance and Mortality in
Treatment Subgroups
Kaplan-Meier estimates of death from any cause by 6-min walk tertile and strati-
ﬁed by treatment group. The data are unadjusted. ICD ¼ implantable cardioverter-
deﬁbrillator.
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mortality was shifted up for every level of 6MW distance
relative to the ICD arm (about 3 per 100 more arrhythmicdeaths in the lowest 6MW tertile, 2 per 100 in the middle
tertile, and almost 5 per 100 in the top tertile). After
adjustment, the prognostic relationship of 6MW distance
became largely ﬂat across the tertiles for ICD and amio-
darone and showed a trend toward increased mortality in the
Table 4 Mortality Rates and HRs for Randomized Treatments, by 6MW Distance Tertile
6MW Distance, m
3-yr KM Mortality Rate ICD vs. Placebo Amiodarone vs. Placebo
ICD Amiodarone Placebo HR (95% CI) p Value HR (95% CI) p Value
<288 28.0 38.7 24.7 1.02 (0.75–1.39) 0.90 1.56 (1.17–2.09) 0.0028
288–386 12.4 16.6 21.6 0.57 (0.39–0.83) 0.0035 0.86 (0.61–1.21) 0.38
>386 7.0 14.2 17.8 0.42 (0.26–0.66) 0.0002 0.68 (0.46–1.02) 0.061
CI ¼ conﬁdence interval; HR ¼ hazard ratio; KM ¼ Kaplan-Meier; other abbreviations as in Table 1.
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2566placebo arm (HR: 1.08 for each 50-m increase in 6MW
distance, p ¼ 0.02).
Discussion
This study conﬁrms and extends previous ﬁndings from the
SCD-HeFT trial showing that the survival beneﬁt of pri-
mary prevention ICD therapy varies importantly depending
upon baseline functional capacity. The original report from
the trial showed that, in pre-speciﬁed subgroup testing,
NYHA functional class III patients did not beneﬁt from
ICD therapy, whereas NYHA functional class II patients
derived a large survival beneﬁt. Implementation of these
ﬁndings in practice and incorporation into clinical guidelines
has been resisted, however, in part because of concerns about
the subjective nature of the NYHA functional class. The
major objective of the present investigation, therefore, was to
evaluate whether the 6MW test, which is generally viewed as
a more objective and reliable means of assessing functional
capacity in heart failure patients, was also able to identify
variations in treatment beneﬁts of ICD therapy similar to
what was previously shown with NYHA functional class.
We found that patients with more advanced heart failure,
as reﬂected by a 6MW distance <288 m (lower tertile), did
not beneﬁt from ICD therapy, whereas those with 6MW
distances >288 m (middle and upper tertiles) beneﬁtedFigure 3 6-Min Walk Distance and Heart Failure Mortality
Kaplan-Meier estimates of 3-year rate of death from heart failure with all other
causes of death censored. Data are unadjusted, and the x-axis shows tertiles
of 6-min walk distance. ICD ¼ implantable cardioverter-deﬁbrillator.substantially. Supplementary analyses looking at mode of
death as classiﬁed by the SCD-HeFT blinded clinical events
committee showed, as expected, that single-lead ICD
therapy had no beneﬁt on heart failure deaths regardless of
6MW distance; however, it substantially and signiﬁcantly
lowered arrhythmic mortality in the top 2 tertiles of 6MW
distance, but not for patients with a 6MW distance <288 m.
Of note, only about one-half of the SCD-HeFT patients
in NYHA functional class III had a 6MW distance
<288m, and 13% were actually in the highest 6MW
distance tertile (>386 m) (Table 2). Conversely, only 50%
of the patients with a 6MW distance <288 m were in
NYHA functional class III. Thus, NYHA functional class
III and 6MW test distance <288 m do not identify the
same patient subgroups. Judged on the basis of the amount
of incremental prognostic information provided, 6MW
distance was modestly more powerful than NYHA func-
tional class (Online Table 1). More prognostic information,
as measured in this way, however, does not necessarily
equate to better clinical treatment selection. At the indi-
vidual patient level, clinicians must therefore continue to
exercise judgment as to the suitability of advanced heart
failure patients for primary prevention ICD therapy,
recognizing that sicker patients are much less likely to
beneﬁt. Judgment as to when the patient is “too sick to
beneﬁt” can reasonably take into account both the NYHA
functional class and the 6MW distance. Establishing which
treatment decision rule (i.e., on the basis of NYHA func-
tional class or on 6MW distance) more often leads to better
survival at the population level cannot be determined from
the SCD-HeFT study data. Another approach to treatment
selection involves the use of multivariable statistical predic-
tion models that can account for the relative importance and
inter-relationships of many more variables in predicting
outcome, such as the Seattle Heart Failure Model (16).
Using this model, Levy et al. (16) divided the SCD-HeFT
group into quintiles on the basis of predicted risk for
all-cause mortality and found that ICD therapy provided
enhanced survival for the bottom 4 quintiles. The top
quintile (highest-risk group), which derived no beneﬁt from
ICD therapy, resembled the subgroup of patients with
6MW distance <288 m in this analysis, with a 6MW me-
dian distance of 280 m, and 61% with NYHA functional
class III.
Our ﬁndings on amiodarone therapy for primary pre-
vention are also consistent with the original SCD-HeFT
Figure 4 6-Min Walk Distance and Arrhythmic Mortality
Kaplan-Meier estimates of 3-year rate of death from arrhythmic cause with all other
causes of death censored. Data are unadjusted. The x-axis shows tertiles of 6-min
walk distance. ICD ¼ implantable cardioverter-deﬁbrillator.
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functional class III patients randomized to amiodarone (p ¼
0.01) (1). In the present analysis, patients with a 6MW
distance <288 m had a 56% increase in mortality with
amiodarone (p ¼ 0.003). In the supplemental analyses
of cause-speciﬁc mortality for patients with a 6MW
distance <288 m, the HR indicated a trend toward
increased heart failure mortality with amiodarone but with
wide conﬁdence limits. In the analysis of arrhythmic deaths,
amiodarone had a neutral effect in patients with a 6MW
distance <288 m (HR: 1.06, p ¼ 0.86). Thus, the reason for
the adverse results for amiodarone therapy in the patients
with more severe heart failure remains unclear, but the
present analysis at least suggests that this ﬁnding was not
dependent on NYHA functional class. It is also possible that
amiodarone increases the risk of bradycardia or ventricular
conduction delays in patients with more advanced heart
failure and signiﬁcant conduction system disease. The
ﬁndings in the dronedarone trial were similar and may
indicate a class effect (17). At minimum, these results sug-
gest that restraint in using amiodarone would be prudent in
more vulnerable patients. It is important to recognize,
however, that amiodarone was used in this trial for primary
prevention and not in patients with atrial and ventricular
arrhythmias.
Taken together, these results suggest the following points.
First, the unadjusted data for both the ICD and amiodarone
arms showed the expected inverse gradient between SWM
distance and mortality, and patterns consistent with this
were seen for both heart failure and arrhythmic deaths. The
difference in all-cause mortality rates between the lowest and
highest 6MW distance tertiles was about 28 per 100 for
amiodarone and 23 per 100 for ICD patients. Second, the
placebo pattern was more complex, because the inverse
gradient of heart failure deaths with 6MW distance (shorter
distance, higher death rate) was partially cancelled out by anincrease in arrhythmic deaths in the top tertile of 6MW
distance, leaving a net modest prognostic 10 per 100 dif-
ference in all-cause mortality between the lowest and highest
6MW tertiles. Third, after multivariable adjustment, the
6MW distance did not retain any independent prognostic
information in the placebo arm due to the smaller absolute
differences between the low- and high-risk groups, which
presumably reﬂect the underlying discordant relationships in
cause-speciﬁc mortality described in the previous text.
An inverse relationship between 6MW distance and
mortality was demonstrated in a sub-study of 898 patients
from the SOLVD (Studies of Left Ventricular Dysfunc-
tion), in which low 6MW distance predicted higher mor-
tality and hospital stay (7). An analysis of 6MW distance
in 331 patients from the FIRST (Flolan International
Randomized Survival Trial) (a trial examining survival in
women with moderate to severe heart failure) also demon-
strated an association between low 6MW distance and
mortality (8). Interestingly, 6MW distance was a more
powerful predictor of death in each of these studies than in
the placebo group in SCD-HeFT, but this may be because
SCD-HeFT patients received more prognosis-modifying
medical therapy. Patients in the SOLVD and FIRST tri-
als were not treated with beta-blockers. The placebo group
in SCD-HeFT had a 7.2% annual mortality (compared to
an annual mortality of 12% in SOLVD and a 6-month
mortality of approximately 26% in FIRST in both men
and women). The SOLVD group more readily matches
the SCD-HeFT group. Mancini et al. (18,19) had similar
ﬁndings regarding predictors and their power in the presence
of beta-blockade. Using peak oxygen consumption rather
than 6MW distance, Mancini et al. (18,19) found it to be a
signiﬁcantly less powerful predictor of mortality in patients
on beta-blockers than in patients not treated with beta-
blockers. It is to be expected that risk predictors lose
power in study groups at lower risk.
This study is notable for being the largest evaluation of
the relationship between 6MW distance and survival in
heart failure patients receiving evidence-based medical
therapy. It is also the ﬁrst to examine the beneﬁt of primary
prevention ICD and amiodarone therapy according to
6MW distance.
Study limitations. Finally, some caveats should be
considered in the interpretation of our ﬁndings. First, the
use of a single variable, either NYHA functional class or
6MW distance, to identify patients who may not beneﬁt
from an ICD and who may be at a particularly increased risk
from amiodarone therapy will never be as accurate or precise
as a method based on a fuller accounting of patient risk using
multivariable models. However, as long as physicians con-
tinue to use simpler decision rules in practice, it will be
important to have an understanding of the key drivers of
treatment beneﬁt and their limitations. Second, patients
with more advanced heart failure, such as those in NYHA
functional class III or with a 6MW distance <288 m, may
be candidates for cardiac resynchronization therapy, and
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therapy has the potential to improve the heart failure state,
our ﬁndings about the beneﬁt of ICD therapy, as well as the
risks of amiodarone, may not apply to such patients. Third,
although the use of distribution-based cutoff values such as
tertiles is useful, the relationships in the data were contin-
uous and do not support the rigid use of cut points. Finally,
the analyses of cause-speciﬁc mortality were done in an
attempt to elucidate complex relationships within our
dataset. Methodologically, there is no completely satisfactory
way to conduct such an analysis because of the distortions
introduced between the baseline variables and causes of
mortality other than the one of interest and because of the
imperfections in our ability to accurately classify the cause of
death, even with the assistance of a blinded clinical events
committee, such as was used in this study. Our analysis used
censoring to exclude deaths other than those upon which the
analysis was focused. When we repeated the analyses
removing patients with these other events from the dataset
instead of censoring them, our results were unchanged. Note
should also be made that these analyses had reduced power
relative to the analyses looking at all deaths.
Conclusions
Patients with a 6MW distance of <288 m did not derive
beneﬁt from either prophylactic ICD implantation or
amiodarone therapy. ICD therapy had a strongly favorable
impact on survival for NYHA functional class II patients
and those with a 6MW distance >288 m. Our ﬁndings
further suggest harm from primary prevention amiodarone
therapy in the group of heart failure patients with the lowest
6MW distance, <288 m. These results conﬁrm and extend
the previously-reported ﬁnding that ICD therapy did not
beneﬁt NYHA functional class III patients in the SCD-
HeFT trial. These data should be included in shared
decision-making with patients for whom they apply.
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For a supplemental table, please see the online version of this article.
